Li XP - Search Results

1

Retraction: MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1.

Xiao L, Zhou H, Li XP, Chen J, Fang C, Mao CX, Cui JJ, Zhang W, Zhou HH, Yin JY, Liu ZQ. Xiao L, et al. Among authors: li xp. Oncotarget. 2024 Aug 26;15:590. doi: 10.18632/oncotarget.28645. Oncotarget. 2024. PMID: 39189975 Free PMC article. No abstract available.

2

The Roles of EXO1 and RPA1 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy.

He J, Wang Z, Wang Y, Zou T, Li XP, Chen J. He J, et al. Among authors: li xp. Dis Markers. 2022 Oct 13;2022:3306189. doi: 10.1155/2022/3306189. eCollection 2022. Dis Markers. 2022. PMID: 36277983 Free PMC article.

3

Activating cGAS-STING pathway with ROS-responsive nanoparticles delivering a hybrid prodrug for enhanced chemo-immunotherapy.

Cao L, Tian H, Fang M, Xu Z, Tang D, Chen J, Yin J, Xiao H, Shang K, Han H, Li X. Cao L, et al. Biomaterials. 2022 Nov;290:121856. doi: 10.1016/j.biomaterials.2022.121856. Epub 2022 Oct 18. Biomaterials. 2022. PMID: 36306685 Free article.

4

Association of variations in the CAT and prognosis in lung cancer patients with platinum-based chemotherapy.

Liu JS, Liu JY, Xiao Q, Li XP, Chen J, Liu ZQ. Liu JS, et al. Among authors: li xp. Front Pharmacol. 2023 Mar 9;14:1119837. doi: 10.3389/fphar.2023.1119837. eCollection 2023. Front Pharmacol. 2023. PMID: 36969849 Free PMC article.

5

Research advances in immune checkpoint drugs for non-small cell lung cancer.

Shen Y, Chen J, Li XP. Shen Y, et al. Among authors: li xp. J Drug Target. 2023 Aug;31(7):700-713. doi: 10.1080/1061186X.2023.2235098. Epub 2023 Jul 14. J Drug Target. 2023. PMID: 37417910 Review.

6

Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy.

Zou T, Liu JY, Qin Q, Guo J, Zhou WZ, Li XP, Zhou HH, Chen J, Liu ZQ. Zou T, et al. Among authors: li xp. Biomedicines. 2023 Nov 24;11(12):3133. doi: 10.3390/biomedicines11123133. Biomedicines. 2023. PMID: 38137354 Free PMC article.

7

Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors.

Chen J, Liu JS, Liu JY, She L, Zou T, Yang F, Li XP, Wang Z, Liu Z. Chen J, et al. Among authors: li xp. J Immunother Cancer. 2024 Jul 11;12(7):e009399. doi: 10.1136/jitc-2024-009399. J Immunother Cancer. 2024. PMID: 38991728 Free PMC article.

8

Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer.

Peng M, Deng J, Li X. Peng M, et al. Mol Cancer. 2024 Nov 15;23(1):256. doi: 10.1186/s12943-024-02167-9. Mol Cancer. 2024. PMID: 39543657 Free PMC article. Review.

9

The Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors.

Li XP, Qu J, Teng XQ, Zhuang HH, Dai YH, Yang Z, Qu Q. Li XP, et al. Int J Biol Sci. 2023 Jan 22;19(4):1036-1048. doi: 10.7150/ijbs.78535. eCollection 2023. Int J Biol Sci. 2023. PMID: 36923930 Free PMC article. Review.

10

Immunomodulatory Therapies for Renal Cell Carcinoma.

Liu M, Wu H, Shangguan D, Jiang Y, Li X, Liu S, Zhou B, Yin T, Gong Z. Liu M, et al. Protein Pept Lett. 2018;25(6):534-547. doi: 10.2174/0929866525666180531080118. Protein Pept Lett. 2018. PMID: 29848257 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,042 results

Search Page

Filters